Madrigal receives positive chmp opinion for resmetirom (rezdiffra™) for the treatment of mash with moderate to advanced liver fibrosis

Conshohocken, pa., june 20, 2025 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq: mdgl), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (mash), today announced that the committee for medicinal products for human use (chmp) of the european medicines agency (ema) has adopted a positive opinion recommending approval of resmetirom (rezdiffra) for the treatment of adults with noncirrhotic mash with moderate to advanced liver fibrosis. the european commission decision is anticipated in august.
MDGL Ratings Summary
MDGL Quant Ranking